Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy in metastatic cervical cancer
NCT03635567Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Pembrolizumab+Chemotherapy with Placebo+Chemotherapy (2 arms). Primary endpoints: Progression-Free Survival at 46 months and Overall Survival at 46 months. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03635567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635567.